Gene Therapy for Inherited Deafness Provides Lasting Hearing Restoration
A multicenter study found a one-time treatment targeting the OTOF gene restored hearing in most participants, with effects lasting up to 2.5 years.
A multicenter study found a one-time treatment targeting the OTOF gene restored hearing in most participants, with effects lasting up to 2.5 years.
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
Researchers achieved a breakthrough by keeping a sliver of the mammalian cochlea alive outside the body, directly revealing the biomechanics of hearing and opening new avenues to treat sensorineural hearing loss.
A look at what we now know about how COVID-19 has been found to affect the auditory system, based on a review of the literature.
In an article published on the ”Discover Magazine” website, author Sarah Katz challenges the view in the scientific community that deafness is a problem that needs to be cured, potentially by new CRISPR technology that could eliminate a TMC1 gene mutation.
Sensorion’s Phase 1/2 Audiogene trial of the gene therapy SENS-501 for infants and toddlers with OTOF-related congenital deafness shows promising early safety and hearing improvement data, particularly in one patient, with a higher dose cohort now underway.
Researchers have developed a novel vibration-based technique to more accurately diagnose balance disorders like Meniere’s disease, especially in aging adults.